Fig 1: Circulating levels of AMH, ROMO1, pro-inflammatory and surrogate cardiovascular/bone damage markers. Data are presented as median and interquartile range (IQR). Mann–Whitney U test was used. (A) HIV-infected women showed significantly lower levels of AMH (1.40 [1.06–1.05] ng/mL vs 1.05 [0.83–1.58] ng/mL; P = .024). (B) HIV-infected women showed significantly higher levels of ROMO1 (4.38 ng/mL vs 6.11 ng/mL; P = .0003). (C) HIV-infected women showed significantly higher levels of TNF-a (2.48 [1.48–3.37] pg/mL vs 3.66 [2.79–4.71] pg/mL; P < .0001). (D) HIV-infected women showed a trend towards higher levels of osteopontin (24.14 [15.57–32.07] ng/mL vs 27.14 [18.53–39.98] ng/mL; P = .068). (E) HIV-infected and uninfected women showed similar levels of IL-6 (1.93 [1.61–3.18] pg/mL vs 1.72 [1.09–3.03] pg/mL; P = .152). (F) HIV-infected and uninfected women showed similar levels of IL-10 (0.45 [0.19–0.65] pg/mL vs 0.36 [0.23–0.59] pg/mL; P = .441). (G) HIV-infected and uninfected women showed similar levels of sVCAM-1 (0.79 [0.59–0.97] µg/mL vs 0.81 [0.65–1.12] µg/mL; P = .198). AMH = anti-Müllerian hormone, HIV = human immunodeficiency virus, ROMO1 = reactive oxygen species modulator 1, sVCAM-1 = soluble vascular cell adhesion molecule 1, TNF-a = tumor necrosis factor a.